REGENXBIO Inc. (NASDAQ:RGNX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have received a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $35.27.

Several research firms have recently weighed in on RGNX. Morgan Stanley restated an “overweight” rating and set a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. Raymond James restated an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research note on Thursday, October 10th. Chardan Capital reiterated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research note on Wednesday. HC Wainwright dropped their price target on REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th.

REGENXBIO Trading Up 4.5 %

NASDAQ RGNX opened at $9.59 on Friday. The stock has a 50 day moving average of $10.24 and a 200-day moving average of $12.07. REGENXBIO has a 12 month low of $8.53 and a 12 month high of $28.80. The company has a market cap of $475.09 million, a PE ratio of -1.91 and a beta of 1.23.

Insiders Place Their Bets

In other news, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the transaction, the director now directly owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. This trade represents a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 13.13% of the company’s stock.

Institutional Investors Weigh In On REGENXBIO

Several institutional investors have recently made changes to their positions in RGNX. Barclays PLC raised its holdings in REGENXBIO by 141.3% in the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after acquiring an additional 67,948 shares in the last quarter. Geode Capital Management LLC raised its stake in REGENXBIO by 4.2% in the third quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company’s stock valued at $11,422,000 after purchasing an additional 44,037 shares in the last quarter. National Bank of Canada FI bought a new stake in REGENXBIO during the third quarter worth about $713,000. Stifel Financial Corp grew its stake in REGENXBIO by 13.3% during the third quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock worth $1,566,000 after buying an additional 17,563 shares in the last quarter. Finally, Redmile Group LLC increased its holdings in REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock valued at $51,327,000 after buying an additional 323,100 shares during the period. 88.08% of the stock is currently owned by institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.